Medications for Gastric Adenocarcinoma

6 results

  • cyramza - ramucirumab solution

    (Ramucirumab)
    Eli Lilly And Company
    Cyramza (ramucirumab) treats advanced gastric, gastro-esophageal junction, non-small cell lung, colorectal, and hepatocellular cancers in adults, used alone or with chemotherapy after prior treatment failure or as first-line therapy for EGFR-mutant NSCLC.
    Medication Details
    Drug Interactions

  • enhertu - fam - trastuzumab deruxtecan - nxki injection, powder, lyophilized, for solution

    (Fam-Trastuzumab Deruxtecan-Nxki)
    Daiichi Sankyo Inc.
    ENHERTU treats HER2-positive and HER2-low/ultralow unresectable or metastatic breast cancer in adults, HER2-mutant non-small cell lung cancer, HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, and HER2-positive (IHC 3+) unresectable or metastatic solid tumors with no satisfactory alternatives.
    Medication Details
    Drug Interactions

  • herceptin - trastuzumab injection, powder, lyophilized, for solution

    (Trastuzumab)
    Genentech, Inc.
    Herceptin treats HER2-overexpressing breast cancer (adjuvant and metastatic) and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma in adults. Used in combination chemotherapy regimens or as a single agent. Requires FDA-approved companion diagnostic for patient selection.
    Medication Details
    Drug Interactions

  • lonsurf - trifluridine and tipiracil tablet, film coated

    (Trifluridine And Tipiracil)
    Taiho Pharmaceutical Co., Ltd.
    Lonsurf treats adults with previously treated metastatic colorectal cancer (alone or with bevacizumab) and metastatic gastric or gastroesophageal junction adenocarcinoma, after prior chemotherapy regimens including fluoropyrimidines, platinum, and irinotecan or taxane.
    Medication Details
    Drug Interactions

  • trazimera - trastuzumab - qyyp

    (Trastuzumab-Qyyp)
    Pfizer Laboratories Div Pfizer Inc
    Trazimera treats HER2-overexpressing breast cancer in adults, including adjuvant node-positive or high-risk node-negative disease, first-line metastatic breast cancer (with paclitaxel), and single-agent use after prior chemotherapy. Also indicated for HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma with cisplatin and capecitabine or 5-fluorouracil.
    Medication Details
    Savings Programs
    1
    Drug Interactions